Literature DB >> 2893900

Advantages of high-dose inhaled budesonide.

E Adelroth, S Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2893900     DOI： 10.1016/s0140-6736(88)91273-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Drug expenditure and new drug introductions: the Swedish experience.

Authors:  U G Gerdtham; M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 2.  The economic aspects of drug delivery in asthma.

Authors:  R J Massie; C M Mellis
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 3.  Inhaled corticosteroid therapy in newly detected mild asthma.

Authors:  P M O'Byrne
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

5.  Why did drug spending increase during the 1990s? A decomposition based on Swedish data.

Authors:  Ulf-G Gerdtham; Douglas Lundin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.